NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (NasdaqGM:IOVA) Announces CFO Resignation
Iovance Biotherapeutics (NasdaqGM:IOVA) recently experienced executive change, with CFO Jean-Marc Bellemin announcing his resignation effective July 10, 2025, following his June 10 decision to pursue other opportunities. Additionally, the Journal of Clinical Oncology published final results from a key clinical trial concerning their T cell therapy, Amtagvi, for advanced melanoma. Despite these developments, Iovance's stock remained flat over the past month. This stability contrasts with a...